High Frequency of Occurrence of CYP2D6 Gene Duplication/Multiduplication Indicating Ultrarapid Metabolism Among Suicide Cases

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Clinical pharmacology and therapy

• Publication date

  2010-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/clpt.2009.216PMID 19907421
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Respiratory depression with tramadol in a patient with renal impairment and CYP2D6 gene duplication.

  2008cited by this paper
• Relation between CYP2D6 phenotype and genotype and personality in healthy volunteers.

  2008cited by this paper
• Effects of the CYP2D6 Gene Duplication on the Pharmacokinetics and Pharmacodynamics of Tramadol

  2008cited by this paper
• Apnea in a child after oral codeine: a genetic variant – an ultra‐rapid metabolizer

  2007cited by this paper
• Cause of death and drug use pattern in deceased drug addicts in Sweden, 2002-2003.

  2007cited by this paper
• A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants

  2006cited by this paper
• Association of CYP2D6 genotypes and personality traits in healthy individuals.

  2006cited by this paper
• Determination of CYP2D6 gene copy number by pyrosequencing.

  2005cited by this paper
• Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations

  2004cited by this paper
• Fatal intoxication cases: cytochrome P 450 2D6 and 2C19 genotype distributions

  2004cited by this paper
• Polymorphic Cytochrome P450 2D6: Humanized Mouse Model and Endogenous Substrates

  2004cited by this paper
• Association between cytochrome P450 2D6 genotype and harm avoidance

  2004cited by this paper
• Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6.

  2004cited by this paper
• Relationship between Type A and B personality and debrisoquine hydroxylation capacity.

  2004cited by this paper
• Identification of CYP2D6 alleles by single nucleotide polymorphism analysis using pyrosequencing

  2003cited by this paper
• Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study

  2003cited by this paper
• Cytochrome P450 2D6 polymorphism and character traits

  2003cited by this paper
• Change from the CYP2D6 extensive metabolizer to the poor metabolizer phenotype during treatment With bupropion.

  2002cited by this paper
• Cytochrome P450 Genotyping by Multiplexed Real-Time DNA Sequencing with Pyrosequencing™ Technology

  2002cited by this paper
• Constitutive expression and localization of the major drug metabolizing enzyme, cytochrome P4502D in human brain.

  2002cited by this paper
• Progesterone oxidation by cytochrome P450 2D isoforms in the brain.

  2001cited by this paper
• Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test

  2001cited by this paper
• Cellular localization and regional distribution of CYP2D6 mRNA and protein expression in human brain.

  2001cited by this paper
• Correctness of prediction of the CYP2D6 phenotype confirmed by genotyping 47 intermediate and poor metabolizers of debrisoquine.

  1998cited by this paper
• Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution.

  1997cited by this paper
• Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences.

  1997cited by this paper
• Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles.

  1996cited by this paper
• Drug-metabolizing enzymes and therapeutic drug monitoring in psychiatry.

  1996cited by this paper
• Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis.

  1995cited by this paper
• Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype.

  1995cited by this paper
• Relationship between personality and debrisoquine hydroxylation capacity

  1993cited by this paper
• Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine.

  1993cited by this paper
• Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population

  1992cited by this paper
• Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S‐mephenytoin

  1992cited by this paper
• Debrisoquine hydroxylation polymorphism and personality.

  1989cited by this paper

• A Validated Whole-Body PBPK Model of Dextromethorphan and Its Metabolites for Genotype-Based Prediction of CYP2D6 Phenotype and Urinary Metabolic Ratio

  2025cites this paper
• CYP2D6 UM phenotype is not related to suicide attempts in depressive patients in secondary psychiatric care

  2025influential citation
• Pharmacogenetic Testing to Optimise Antidepressant Treatment in Children and Adolescents: A Narrative Review

  2024cites this paper
• CYP2D6 and CYP2C19 ultrarapid metabolisms are associated with suicide attempts in schizophrenia.

  2024cites this paper
• Harnessing Pharmacogenomics in Clinical Research on Psychedelic‐Assisted Therapy

  2024cites this paper
• Pharmacogenomics and the Management of Mood Disorders—A Review

  2023cites this paper
• Utility of pharmacogenetic testing to optimise antidepressant pharmacotherapy in youth: a narrative literature review

  2023cites this paper
• A one-year follow-up study of treatment-compliant suicide attempt survivors: relationship of CYP2D6-CYP2C19 and polypharmacy with suicide reattempts

  2022cites this paper
• Physiologically based pharmacokinetic (PBPK) modeling of the role of CYP2D6 polymorphism for metabolic phenotyping with dextromethorphan

  2022cites this paper
• Cytochrome P450 polymorphisms with impact in cardiovascular drugs metabolisms in European populations

  2022cites this paper
• Psychoactive Medication, Violence, and Variant Alleles for Cytochrome P450 Genes

  2021cites this paper
• Influence of cytochrome P450 2D6 polymorphism on hippocampal white matter and treatment response in schizophrenia

  2021cites this paper
• Direct superacid-promoted difluoroethylation of aromatics.

  2021cites this paper
• Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests): focus on antidepressants

  2021cites this paper
• Analysis of the Deleterious Single-Nucleotide Polymorphisms Associated With Antidepressant Efficacy in Major Depressive Disorder

  2020cites this paper
• The Systems Biology of Drug Metabolizing Enzymes and Transporters: Relevance to Quantitative Systems Pharmacology

  2020cites this paper
• Human CYP2D6 Is Functional in Brain In Vivo: Evidence from Humanized CYP2D6 Transgenic Mice

  2020cites this paper
• Analysis of Lithuanian CYP2D6 polymorphism and its relevance to psychiatric care of the local population

  2019cites this paper
• Defining screening panel of functional variants of CYP1A1, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 genes in Serbian population

  2019cites this paper
• Treatment Emergent Violence To Self And Others; A Literature Review of Neuropsychiatric Adverse Reactions For Antidepressant And Neuroleptic Psychiatric Drugs And General Medications.

  2019cites this paper
• A pharmacogenetic intervention for the improvement of the safety profile of antipsychotic treatments

  2019cites this paper
• Description du polymorphisme génétique des cytochromes P450 2C19 et 2D6 (CYP2C19 et CYP2D6) d'une large cohorte française de patients suivis en psychiatrie

  2019cites this paper
• Consequences of CYP2D6 Copy-Number Variation for Pharmacogenomics in Psychiatry

  2019cites this paper
• The Importance of Ethnicity Definitions and Pharmacogenomics in Ethnobridging and Pharmacovigilance

  2019cites this paper
• Completed suicides of citalopram users—the role of CYP genotypes and adverse drug interactions

  2018cites this paper
• Integration of Medical and Dental Care and Patient Data

  2018cites this paper
• Pharmacoresistant Severe Mental Health Disorders in Children and Adolescents: Functional Abnormalities of Cytochrome P450 2D6

  2018cites this paper
• Out‐compute drug side effects: Focus on cytochrome P450 2D6 modeling

  2018cites this paper
• The engagement of brain cytochrome P450 in the metabolism of endogenous neuroactive substrates: a possible role in mental disorders

  2018cites this paper
• Para-methoxymethamphetamine (PMMA): A study of risk factors for fatal intoxication with emphasis on metabolite pattern and CYP genetics

  2018cites this paper
• Post-mortem Pharmacogenetics - Citalopram-positive Suicides as a Model Population

  2018cites this paper
• Pharmacogenetics of neurological and psychiatric diseases at older age: has the time come?

  2017cites this paper
• Predicting CYP2D6 phenotype from resting brain perfusion images by gradient boosting.

  2017cites this paper
• Optimization of pyrosequencing method for copy number analysis of CYP2D6

  2017cites this paper
• Psychotropic drugs and CYP2D6 in late-life psychiatric and neurological disorders. What do we know?

  2017cites this paper
• Single Nucleotide Polymorphisms and the Central Nervous System: Potential Biomarkers in Identifying Suicide Risk.

  2017cites this paper
• Is toxicity of PMMA (paramethoxymethamphetamine) associated with cytochrome P450 pharmacogenetics?

  2016cites this paper
• Personalized prescribing: a new medical model for clinical implementation of psychotropic drugs

  2016cites this paper
• High Frequency of CYP2D6 Ultrarapid Metabolizer Genotype in the Finnish Population

  2016cites this paper
• The ABCB1, rs9282564, AG and TT Genotypes and the COMT, rs4680, AA Genotype are Less Frequent in Deceased Patients with Opioid Addiction than in Living Patients with Opioid Addiction

  2016cites this paper
• High frequency of CYP2D6 ultrarapid metabolizers in Spain: controversy about their misclassification in worldwide population studies

  2016cites this paper
• Progress and prospects in pharmacogenetics of antidepressant drugs

  2016cites this paper
• CYP2D6 ultra-rapid metabolizer phenotype not associated with attempted suicide in a large sample of psychiatric inpatients.

  2016cites this paper
• Psychiatry meets pharmacogenetics for the treatment of revolving door patients with psychiatric disorders

  2016cites this paper
• Emerging roles for brain drug-metabolizing cytochrome P450 enzymes in neuropsychiatric conditions and responses to drugs

  2016cites this paper
• The pharmacogenetic road to avoid adverse drug reactions and therapeutic failures in revolving door patients with psychiatric illnesses: focus on the CYP2D6 isoenzymes

  2016cites this paper
• Pharmacogenetic Studies of Suicide: Potential Relevance of Main Polymorphic CYPs and ABCB1

  2016cites this paper
• Genetic Polymorphism of Cytochrome P450 2D6*4 and 2D6*5 in an Adult Population Sample from Costa Rica

  2016cites this paper
• Personalizing supportive care in oncology patients using pharmacogenetic-driven treatment pathways.

  2016cites this paper
• Pharmacogenetic Testing

  2016cites this paper
• Complex Membrane Channel Blockade: A Unifying Hypothesis for the Prodromal and Acute Neuropsychiatric Sequelae Resulting from Exposure to the Antimalarial Drug Mefloquine

  2015cites this paper
• Identificación de predictores farmacogenéticos en la respuesta terapéutica a Fluoxetina en niños y adolescentes

  2015cites this paper
• Pharmacogenetics of Major Depressive Disorder: Top Genes and Pathways Toward Clinical Applications

  2015cites this paper
• Sex hormones regulate cerebral drug metabolism via brain miRNAs: down‐regulation of brain CYP2D by androgens reduces the analgesic effects of tramadol

  2015cites this paper
• Increased prevalence of functional minor allele variants of drug metabolizing CYP2B6 and CYP2D6 genes in Roma population samples

  2015cites this paper
• Polymorphism in CYP2D6 and CYP2C19, members of the cytochrome P450 mixed‐function oxidase system, in the metabolism of psychotropic drugs

  2015cites this paper
• Computational predictions of the site of metabolism of cytochrome P450 2D6 substrates: comparative analysis, molecular docking, bioactivation and toxicological implications

  2015cites this paper
• A Genome-Wide Copy Number Variant Study of Suicidal Behavior

  2015cites this paper
• Development of a Tetraplex PCR Assay for CYP2D6 Genotyping in Degraded DNA Samples

  2014cites this paper
• Genetic polymorphisms of CYP2C8, CYP2C9 and CYP2C19 in Ecuadorian Mestizo and Spaniard populations: a comparative study

  2014cites this paper
• An overview of the neurobiology of suicidal behaviors as one meta-system

  2014cites this paper
• Genetic variation in CYP3A43 is associated with response to antipsychotic medication

  2014cites this paper
• CYP2D6 variation, behaviour and psychopathology: implications for pharmacogenomics-guided clinical trials.

  2014cites this paper
• CYP2D6 polymorphism and mental and personality disorders in suicide attempters.

  2014cites this paper
• Influence of CYP2D6 and CYP2C19 genotypes on venlafaxine metabolic ratios and stereoselective metabolism in forensic autopsy cases

  2014cites this paper
• Interethnic variability of CYP2D6 alleles and of predicted and measured metabolic phenotypes across world populations

  2014cites this paper
• Pharmacogenomics of Cytochrome P450 Dependent Metabolism of Endogenous Compounds: Implications for Behavior, Psychopathology and Treatment

  2014cites this paper
• A combined high CYP2D6-CYP2C19 metabolic capacity is associated with the severity of suicide attempt as measured by objective circumstances

  2014cites this paper
• Medicolegal Autopsies and Pharmacogenetics

  2014cites this paper
• CYP2D6 : clinical implications in neuropsychiatry

  2014cites this paper
• Towards the clinical implementation of pharmacogenetics in bipolar disorder

  2014cites this paper
• Neither Cytochrome P450 Family Genes nor Neuroendocrine Factors could Independently Predict the SSRIs Treatment in the Chinese Han Population

  2014cites this paper
• Polymorphic expression of CYP2C19 and CYP2D6 in the developing and adult human brain causing variability in cognition, risk for depression and suicide: the search for the endogenous substrates.

  2014cites this paper
• The endogenous substrates of brain CYP2D.

  2014cites this paper
• A poor metabolizer of both CYP2C19 and CYP2D6 identified by mechanistic pharmacokinetic simulation in a fatal drug poisoning case involving venlafaxine.

  2013cites this paper
• The impact of Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes on suicide attempt and suicide risk—a European multicentre study on treatment-resistant major depressive disorder

  2013cites this paper
• Impact of cytochrome P450 genes on suicide attempt and risk

  2013cites this paper
• The Expression and Regulation of CYP2D in a Monkey Model of Ethanol and Nicotine Exposure

  2013cites this paper
• Importance of Ethnicity Definitions and Pharmacogenomics in Ethnobridging

  2013cites this paper
• Decreased hippocampal volume and increased anxiety in a transgenic mouse model expressing the human CYP2C19 gene

  2013cites this paper
• CYP2D6 genetic polymorphism and psychiatry patients' hospitalization period.

  2013cites this paper
• Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic

  2013cites this paper
• Influence of CYP2D6 and CYP2C19 gene variants on antidepressant response in obsessive-compulsive disorder

  2013cites this paper
• ABCB1 gene polymorphisms are associated with fatal intoxications involving venlafaxine but not citalopram

  2013cites this paper
• CYP2C19 and brain development : implications for susceptibility to anxiety in a transgenic mouse model

  2013cites this paper
• Impact of metabolizing enzymes on drug response of endocrine therapy in breast cancer

  2013cites this paper
• CYP2D6 POLYMORPHISM AND MENTAL AND PERSONALITY DISORDERS IN SUICIDE ATTEMPTERS

  2013cites this paper
• Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants

  2013cites this paper
• Genetic variability of drug-metabolizing enzymes: the dual impact on psychiatric therapy and regulation of brain function

  2013cites this paper
• Toxicogenetics—cytochrome P450 microarray analysis in forensic cases focusing on morphine/codeine and diazepam

  2013cites this paper
• The Importance of Ethnicity Definitions and Pharmacogenomics in Ethnobridging

  2013cites this paper
• Challenges in pharmacogenetics

  2013cites this paper
• The association between CYP2D6 genotype and switching antipsychotic medication to clozapine

  2013cites this paper
• Genetic variation in CYP2D6 impacts neural activation during cognitive tasks in humans

  2012cites this paper
• Pharmacogenomics of CYP 2 D 6 : Molecular Genetics , Interethnic Differences and Clinical Importance

  2012cites this paper
• CYP2D6 and the severity of suicide attempts.

  2012cites this paper
• Genetic determinants of antipsychotic drug response

  2012cites this paper
• CYP2D6 Ultrarapid Metabolism and Suicide

  2012cites this paper
• CYP2C19 genetics in fatal carisoprodol intoxications

  2012cites this paper
• Population differences in major functional polymorphisms of pharmacokinetics/pharmacodynamics-related genes in Eastern Asians and Europeans: implications in the clinical trials for novel drug development.

  2012cites this paper